Status:
ACTIVE_NOT_RECRUITING
Outcome of ADPKD With Octreotide LAR
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Conditions:
Autosomal Dominant Polycystic Kidney
Eligibility:
All Genders
18+ years
Brief Summary
In this observational, retrospective study we will primarily aim at evaluating the independent role of baseline clinical and laboratory parameters, including TKV, in the prediction of long term chroni...
Detailed Description
Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most common hereditary cystic renal disease, has an incidence of 1 in 800 live births and accounts for 7-10% of patients on dialysis in develo...
Eligibility Criteria
Inclusion
- ADPKD patients with criteria for the prescription of octreotide LAR according to Law n. 648, 23 December 1996: ≥ 18 year-old; Clinical and instrumental diagnosis of ADPKD; Estimated GFR (MDRD): ≥ 15 ml/min/1.73m2 and \<30 ml/min/1.73m2.
- Written informed consent to participate in the observational study and to the use of recorded data for research purposes.
- Availability of an adequate (for quantitative volumetric analyses) non-contrast enhanced Computed Tomography (CT) scan acquired before starting octreotide-LAR therapy.
- Follow-up of at least six months (eg. up to the first post-treatment GFR evaluation from the start of chronic octreotide LAR treatment).
Exclusion
- Legal incapacity or limited legal capacity.
- Contraindications to the prescription of octreotide LAR according to Law n. 648, 23 December 1996.
Key Trial Info
Start Date :
February 12 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06193616
Start Date
February 12 2024
End Date
December 1 2025
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST HPG23 - Unità di Nefrologia
Bergamo, BG, Italy, 24100